Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

EYPT

EyePoint Pharmaceuticals Inc

Sep 20 • 03:02PM ET

9.16

Dollar change -0.02
Percentage change -0.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IWO VTWO XPH VHT IWC NUSC

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	7.51%	Shs Outstand	53.52M	Perf Week	0.66%
Market Cap	490.24M	Forward P/E	-	EPS next Y	-3.19	Insider Trans	54.64%	Shs Float	49.50M	Perf Month	1.22%
Income	-86.82M	PEG	-	EPS next Q	-0.56	Inst Own	103.62%	Short Float	18.41%	Perf Quarter	8.15%
Sales	50.39M	P/S	9.73	EPS this Y	-30.04%	Inst Trans	-0.27%	Short Ratio	12.79	Perf Half Y	-60.89%
Book/sh	4.38	P/B	2.09	EPS next Y	-34.65%	ROA	-34.74%	Short Interest	9.11M	Perf Year	6.88%
Cash/sh	5.24	P/C	1.75	EPS next 5Y	-	ROE	-60.81%	52W Range	5.67 - 30.99	Perf YTD	-60.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.57%	ROI	-34.66%	52W High	-70.44%	Beta	1.60
Dividend TTM	-	Quick Ratio	4.69	Sales past 5Y	69.47%	Gross Margin	91.35%	52W Low	61.55%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	4.75	EPS Y/Y TTM	36.56%	Oper. Margin	-195.71%	RSI (14)	56.19	Volatility	6.97% 7.51%
Employees	121	Debt/Eq	0.10	Sales Y/Y TTM	34.98%	Profit Margin	-172.29%	Recom	1.17	Target Price	36.64
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	5.02%	Payout	-	Rel Volume	0.62	Prev Close	9.18
Sales Surprise	-10.66%	EPS Surprise	-14.97%	Sales Q/Q	4.09%	Earnings	Aug 07 BMO	Avg Volume	712.59K	Price	9.16
SMA20	5.41%	SMA50	2.96%	SMA200	-44.24%	Trades		Volume	379,317	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Sep-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 07:00AM	EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors (GlobeNewswire)
Aug-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 07:00AM	EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.90%
08:15AM	Loading…
Aug-07-24 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:09AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-26-24 08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYU (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
Jun-18-24 07:00AM	EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 (GlobeNewswire)
Jun-17-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 07:00AM	EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire) +6.18%
02:35AM	Loading…
02:35AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com)
May-17-24 02:34AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com) -5.43%
May-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-24 02:34PM	EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges (GuruFocus.com)
May-08-24 01:54PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:48AM	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating (MT Newswires)
07:23AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
May-07-24 09:32AM	Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating (MT Newswires) +5.98%
May-06-24 11:00AM	Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? (Benzinga) -43.26%
08:42AM	EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint (MT Newswires)
07:00AM	EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy (GlobeNewswire)
Apr-23-24 01:21PM	Hedge Fund and Insider Trading News: David Tepper, Ray Dalio, RA Capital Management, Millennium Management, Biohaven Ltd (BHVN), EyePoint Pharmaceuticals Inc. (EYPT), and More (Insider Monkey)
Apr-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 07:00AM	EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists (GlobeNewswire)
07:00AM	Loading…
Mar-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-24 01:00PM	5 Growth Stocks Under $50 for March 2024 (Investopedia)
Mar-08-24 09:31AM	EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:39PM	Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:25PM	EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 (GuruFocus.com)
12:53PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:30AM	Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics (Zacks)
07:20AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -7.46%
Feb-29-24 10:00AM	Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know (Zacks)
08:50AM	Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going (Zacks)
07:00AM	EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 (GlobeNewswire)
04:19AM	20 Countries With Worst Vision Problems (Insider Monkey)
Feb-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +7.98%
Feb-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 12:00PM	Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice (Zacks)
Feb-13-24 09:55AM	Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet (Zacks)
08:50AM	Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength (Zacks)
Feb-03-24 04:20PM	EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Jan-31-24 07:00AM	EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 11:02PM	EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares (GuruFocus.com)
Jan-25-24 11:51PM	EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares (GuruFocus.com) +6.31%
Jan-24-24 07:01PM	EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 35,066 Shares (GuruFocus.com)
Jan-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:14PM	EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 22,913 Shares (GuruFocus.com) +11.79%
Jan-10-24 07:00AM	EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema (GlobeNewswire) -5.78%
Dec-20-23 07:00AM	EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-23 12:45PM	Hedge Fund and Insider Trading News: Leon Cooperman, Christopher Hohn, Ken Griffin, D.E. Shaw, Ryman Hospitality Properties Inc (RHP), EyePoint Pharmaceuticals, Inc. (EYPT), and More (Insider Monkey) +7.84%
Dec-11-23 12:00PM	EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-08-23 04:01PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -9.58%
09:55AM	Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Trade (Zacks)
08:50AM	What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing' (Zacks)
Dec-07-23 01:07PM	Insider Sell Alert: Chief Corp Dev. & Strat. ... (GuruFocus.com) +9.46%
Dec-05-23 08:18PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire) +9.08%
09:18AM	EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data (Zacks)
Dec-04-23 04:06PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +177.46%
11:37AM	Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today? (InvestorPlace)
07:00AM	EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints (GlobeNewswire)
06:19AM	EyePoint sees stock surge on AMD drug trial data (BioPharma Dive)
Nov-21-23 09:55AM	Does EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect? (Zacks) -13.44%
Nov-16-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.62%
Nov-02-23 07:04PM	EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.31%
Nov-01-23 09:33AM	EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Results (GuruFocus.com) +20.27%
07:06AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Oct-31-23 07:00AM	EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023 (GlobeNewswire) +5.43%
Oct-30-23 07:00AM	EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023 (GlobeNewswire)
Oct-25-23 07:00AM	EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023 (GlobeNewswire) -14.21%
Oct-16-23 07:00AM	EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team (GlobeNewswire)
Sep-18-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.82%
Sep-11-23 03:20PM	Why Shares of EyePoint Pharmaceuticals Were Rising Monday (Motley Fool) +16.15%
07:00AM	EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 (GlobeNewswire)
Aug-30-23 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +5.33%
Aug-23-23 07:34PM	EyePoint Pharmaceuticals: A Significantly Overvalued Stock? (GuruFocus.com) -20.38%
Aug-16-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-09-23 07:00AM	EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire) +6.14%
Aug-02-23 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-27-23 07:00AM	EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit (GlobeNewswire)
Jul-26-23 07:00AM	EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire) -5.90%
Jul-17-23 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-23 07:35PM	Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2023 (TipRanks) +13.31%
07:00AM	EyePoint Pharmaceuticals Announces Chief Executive Officer Transition (GlobeNewswire)
Jun-05-23 07:00AM	EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy (GlobeNewswire)
May-31-23 07:00AM	EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-18-23 10:29PM	Q1 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.04%
09:02AM	EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties (Benzinga)

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DICICCO WENDY F	Director	Aug 20 '24	Buy	7.79	2,567	19,997	9,967	Aug 21 04:32 PM
ANDO GORAN	Director	Aug 21 '24	Buy	7.95	5,000	39,750	13,150	Aug 21 04:01 PM
Zaderej Karen L.	Director	Aug 19 '24	Buy	7.98	12,500	99,750	16,500	Aug 21 04:01 PM
Lurker Nancy	Director	Aug 16 '24	Buy	7.88	3,173	25,003	97,635	Aug 20 04:04 PM
GUYER DAVID R	Director	Jul 12 '24	Option Exercise	3.34	9,775	32,646	13,475	Jul 16 04:24 PM
GUYER DAVID R	Director	Jul 12 '24	Sale	10.06	11,625	116,995	1,850	Jul 16 04:24 PM
Duker Jay S.	President and CEO	Jul 10 '24	Option Exercise	0.00	16,666	0	46,086	Jul 12 05:04 PM
Lurker Nancy	Executive Vice Chair	Jul 10 '24	Option Exercise	0.00	11,111	0	94,462	Jul 12 05:03 PM
Zaderej Karen L.	Director	Jul 11 '24	Option Exercise	0.00	2,000	0	4,000	Jul 12 05:00 PM
ADAMIS ANTHONY P	Director	Jun 23 '24	Option Exercise	0.00	2,000	0	4,000	Jun 25 04:16 PM
GUYER DAVID R	Director	Jun 03 '24	Option Exercise	3.34	9,775	32,646	15,325	Jun 04 04:28 PM
GUYER DAVID R	Director	Jun 03 '24	Sale	10.30	11,625	119,705	3,700	Jun 04 04:28 PM
Elston George	Chief Financial Officer	May 25 '24	Option Exercise	0.00	7,500	0	51,107	May 28 04:22 PM
GUYER DAVID R	Director	May 14 '24	Option Exercise	3.34	9,775	32,646	17,175	May 16 05:19 PM
GUYER DAVID R	Director	May 14 '24	Sale	12.65	11,625	147,045	5,550	May 16 05:19 PM
Cormorant Asset Management, LP	10% Owner	May 06 '24	Buy	11.86	850,000	10,081,721	8,325,000	May 08 04:23 PM
Cormorant Asset Management, LP	10% Owner	Apr 18 '24	Buy	18.03	581,765	10,489,446	7,475,000	Apr 22 04:00 PM
Paggiarino Dario A.	Chief Medical Officer	Mar 30 '24	Option Exercise	0.00	50,404	0	92,626	Apr 02 05:27 PM
Lurker Nancy	Executive Vice Chair	Feb 09 '24	Option Exercise	0.00	37,534	0	172,975	Feb 13 05:40 PM
Paggiarino Dario A.	Chief Medical Officer	Feb 09 '24	Option Exercise	0.00	10,800	0	47,305	Feb 13 05:39 PM
Jones David Scott	SVP & Chief Commercial Officer	Feb 09 '24	Option Exercise	0.00	9,967	0	48,572	Feb 13 05:38 PM
Elston George	Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	10,800	0	46,799	Feb 13 05:38 PM
Duker Jay S.	President and CEO	Feb 09 '24	Option Exercise	0.00	11,967	0	55,453	Feb 13 05:37 PM
Jones David Scott	SVP & Chief Commercial Officer	Feb 02 '24	Option Exercise	11.47	209	2,397	38,171	Feb 05 05:15 PM
Jones David Scott	SVP & Chief Commercial Officer	Feb 02 '24	Sale	28.49	209	5,954	37,962	Feb 05 05:15 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 26 '24	Option Exercise	13.06	49,325	644,047	85,830	Jan 30 04:53 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 26 '24	Sale	25.66	49,325	1,265,539	36,505	Jan 30 04:53 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 26 '24	Option Exercise	6.82	26,017	177,398	63,979	Jan 29 05:54 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 26 '24	Sale	25.38	26,017	660,370	37,962	Jan 29 05:54 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 25 '24	Option Exercise	13.02	600	7,809	37,105	Jan 29 05:51 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 25 '24	Sale	25.00	600	15,000	36,505	Jan 29 05:51 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 24 '24	Option Exercise	8.04	11,300	90,822	49,262	Jan 26 05:03 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 25 '24	Option Exercise	8.08	600	4,848	38,562	Jan 26 05:03 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 24 '24	Sale	25.01	11,300	282,621	37,962	Jan 26 05:03 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 25 '24	Sale	25.00	600	15,000	37,962	Jan 26 05:03 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 24 '24	Option Exercise	13.01	11,251	146,426	47,756	Jan 25 06:26 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 23 '24	Option Exercise	13.04	5,135	66,954	41,640	Jan 25 06:26 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 24 '24	Sale	25.01	11,251	281,415	36,505	Jan 25 06:26 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 23 '24	Sale	25.00	5,135	128,375	36,505	Jan 25 06:26 PM
Lurker Nancy	Executive Vice Chair	Jan 24 '24	Sale	24.98	29,956	748,250	135,441	Jan 25 06:24 PM
Lurker Nancy	Executive Vice Chair	Jan 23 '24	Sale	24.97	5,044	125,950	165,397	Jan 25 06:24 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 22 '24	Option Exercise	10.34	34,166	353,359	72,128	Jan 24 04:50 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 23 '24	Option Exercise	7.54	900	6,790	38,862	Jan 24 04:50 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 22 '24	Sale	22.62	34,166	772,691	37,962	Jan 24 04:50 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 23 '24	Sale	25.00	900	22,500	37,962	Jan 24 04:50 PM
Ocumension Therapeutics	Director	Jan 11 '24	Sale	19.45	1,910,500	37,159,225	100,221	Jan 16 06:55 PM
Liu Ye	Director	Jan 11 '24	Sale	19.45	1,910,500	37,159,225	100,221	Jan 16 06:01 PM
Cormorant Asset Management, LP	10% Owner	Jan 11 '24	Buy	19.75	750,000	14,812,500	6,893,235	Jan 11 04:00 PM
Cormorant Asset Management, LP	10% Owner	Jan 09 '24	Buy	21.32	105,000	2,238,600	6,143,235	Jan 11 04:00 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 08 '24	Option Exercise	3.26	22,913	74,696	59,418	Jan 10 04:53 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 08 '24	Sale	21.13	22,913	484,124	36,505	Jan 10 04:53 PM
Paggiarino Dario A.	Chief Medical Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	40,992	Jan 09 09:28 PM
Lurker Nancy	Executive Vice Chair	Jan 06 '24	Option Exercise	0.00	75,133	0	193,484	Jan 09 09:17 PM
Pine Michael Craig	Chief Corp Dev.&Strat. Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	19,628	Jan 09 09:11 PM
Jones David Scott	SVP & Chief Commercial Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	42,109	Jan 09 09:09 PM
Duker Jay S.	President and CEO	Jan 06 '24	Option Exercise	0.00	20,793	0	50,014	Jan 09 09:07 PM
Elston George	Chief Financial Officer	Jan 06 '24	Option Exercise	0.00	15,285	0	40,219	Jan 09 09:04 PM
Paggiarino Dario A.	Chief Medical Officer	Dec 13 '23	Option Exercise	10.13	1,458	14,770	27,165	Dec 15 05:14 PM
Paggiarino Dario A.	Chief Medical Officer	Dec 13 '23	Sale	20.00	1,458	29,160	25,707	Dec 15 05:14 PM
Cormorant Asset Management, LP	10% Owner	Dec 08 '23	Buy	17.00	588,235	9,999,995	6,038,235	Dec 12 04:52 PM
Ocumension Therapeutics	Director	Dec 05 '23	Sale	19.91	733,758	14,609,122	2,276,963	Dec 07 09:21 PM
Ocumension Therapeutics	Director	Dec 06 '23	Sale	18.41	266,242	4,901,515	2,010,721	Dec 07 09:21 PM
Liu Ye	Director	Dec 05 '23	Sale	19.91	733,758	14,609,122	2,276,963	Dec 07 09:03 PM
Liu Ye	Director	Dec 06 '23	Sale	18.41	266,242	4,901,515	2,010,721	Dec 07 09:03 PM
Pine Michael Craig	Chief Corp Dev.&Strat. Officer	Dec 04 '23	Option Exercise	12.62	45,000	567,900	50,343	Dec 06 05:20 PM
Pine Michael Craig	Chief Corp Dev.&Strat. Officer	Dec 04 '23	Sale	22.00	45,000	990,000	5,343	Dec 06 05:20 PM
Paggiarino Dario A.	Chief Medical Officer	Dec 04 '23	Option Exercise	10.13	30,625	310,231	56,332	Dec 06 05:19 PM
Paggiarino Dario A.	Chief Medical Officer	Dec 04 '23	Sale	22.00	30,625	673,750	25,707	Dec 06 05:19 PM
Lurker Nancy	Executive Vice Chair	Dec 04 '23	Sale	20.76	20,000	415,200	170,559	Dec 06 05:18 PM
Cormorant Asset Management, LP	10% Owner	Dec 04 '23	Buy	21.82	1,919,057	41,874,151	5,450,000	Dec 06 04:39 PM

Open in Screener

AXGN

Axogen Inc.

Sep 20 • 03:02PM ET

14.40

Dollar change -0.27
Percentage change -1.84	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO IHI SCHA VTWO HTEC DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	5.71%	Shs Outstand	43.12M	Perf Week	4.42%
Market Cap	631.15M	Forward P/E	86.40	EPS next Y	0.17	Insider Trans	-2.22%	Shs Float	41.33M	Perf Month	11.46%
Income	-16.54M	PEG	-	EPS next Q	0.01	Inst Own	80.60%	Short Float	4.78%	Perf Quarter	105.71%
Sales	173.48M	P/S	3.64	EPS this Y	89.22%	Inst Trans	4.15%	Short Ratio	4.54	Perf Half Y	87.74%
Book/sh	2.18	P/B	6.60	EPS next Y	1009.11%	ROA	-8.69%	Short Interest	1.98M	Perf Year	176.92%
Cash/sh	0.62	P/C	23.26	EPS next 5Y	-	ROE	-17.15%	52W Range	3.45 - 15.08	Perf YTD	110.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.44%	ROI	-10.15%	52W High	-4.49%	Beta	1.13
Dividend TTM	-	Quick Ratio	2.32	Sales past 5Y	13.87%	Gross Margin	77.79%	52W Low	317.39%	ATR (14)	0.55
Dividend Ex-Date	Jan 27, 2010	Current Ratio	3.51	EPS Y/Y TTM	30.61%	Oper. Margin	-7.04%	RSI (14)	73.13	Volatility	4.01% 3.87%
Employees	428	Debt/Eq	0.72	Sales Y/Y TTM	17.26%	Profit Margin	-9.53%	Recom	1.14	Target Price	15.86
Option/Short	Yes / Yes	LT Debt/Eq	0.70	EPS Q/Q	71.69%	Payout	-	Rel Volume	0.77	Prev Close	14.67
Sales Surprise	10.48%	EPS Surprise	178.12%	Sales Q/Q	25.57%	Earnings	Aug 08 BMO	Avg Volume	434.68K	Price	14.40
SMA20	8.05%	SMA50	29.45%	SMA200	67.08%	Trades		Volume	288,803	Change	-1.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11
Nov-07-16	Reiterated	Wedbush	Outperform	$10 → $12
Nov-03-16	Downgrade	Lake Street	Buy → Hold	$9

Show Previous Ratings

Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Loading…
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
08:37AM	Loading…
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:50PM	Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix (GlobeNewswire)
Apr-16-24 07:00AM	Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Mar-08-24 11:55PM	Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN) (GuruFocus.com)
Mar-06-24 08:20AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 09:27PM	Q4 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) -15.11%
11:53AM	AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:38AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023 (GuruFocus.com)
07:00AM	Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-28-24 08:50AM	AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-26-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-13-24 04:30PM	Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 (GlobeNewswire)
Feb-12-24 08:50AM	Here's Why Momentum in AxoGen (AXGN) Should Keep going (Zacks)
Feb-06-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-24 04:15PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength (Zacks)
Jan-18-24 05:00PM	Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap (GlobeNewswire) +7.86%
Jan-04-24 04:45PM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 (GlobeNewswire) +26.67%
04:40PM	Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 (GlobeNewswire)
04:35PM	Axogen Announces Promotions on Research and Development Team (GlobeNewswire)
Dec-26-23 04:15PM	Axogen, Inc. Appoints Kathy Weiler to its Board of Directors (GlobeNewswire)
Dec-06-23 07:00AM	Axogen Announces Transition of Finance Team Leadership (GlobeNewswire) +5.19%
Dec-01-23 05:00PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.04%
Nov-20-23 07:00AM	Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-08-23 09:41AM	AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 11:01PM	Q3 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +36.90%
08:04AM	Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports 2023 Third Quarter Financial Results (GlobeNewswire)
Nov-02-23 10:00AM	Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.26%
Oct-31-23 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-18-23 07:00AM	Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023 (GlobeNewswire)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +5.28%
Sep-28-23 08:21AM	AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last? (Zacks)
Sep-05-23 07:00AM	Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector (GlobeNewswire)
Aug-31-23 07:00AM	Axogen to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 07:00AM	Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio (GlobeNewswire)
Aug-10-23 03:03PM	ArrowMark Colorado Holdings LLC Boosts Stake in Axogen Inc (GuruFocus.com) -6.51%
12:05PM	AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 10:59AM	The past five years for AxoGen (NASDAQ:AXGN) investors has not been profitable (Simply Wall St.) -19.44%
05:57AM	Q2 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:25PM	AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	AxoGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	Axogen, Inc. Reports 2023 Second Quarter Financial Results (GlobeNewswire)
Aug-03-23 05:55PM	Artivion (AORT) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-27-23 07:00AM	Axogen to Participate at Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire) -6.83%
Jul-26-23 07:00AM	Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023 (GlobeNewswire)
Jun-10-23 10:42AM	With 71% ownership, AxoGen, Inc. (NASDAQ:AXGN) boasts of strong institutional backing (Simply Wall St.)
Jun-09-23 09:55AM	Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet (Zacks)
May-24-23 07:00AM	Axogen to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-12-23 07:00AM	Axogen to Participate at JMP Securities Life Sciences Conference (GlobeNewswire)
May-09-23 08:35AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:34AM	AxoGen: Q1 Earnings Snapshot (AP Finance)
07:00AM	Axogen, Inc. Reports 2023 First Quarter Financial Results (GlobeNewswire)
Apr-18-23 04:05PM	Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023 (GlobeNewswire)
07:25AM	Even With A 26% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely (Simply Wall St.)
Mar-17-23 04:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 06:30AM	AxoGen Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Mar-14-23 11:23PM	Q4 2022 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +11.95%
07:00AM	Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Mar-06-23 07:00AM	Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel (GlobeNewswire)
Mar-02-23 04:00PM	Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023 (GlobeNewswire)
Mar-01-23 09:21AM	AxoGen (NASDAQ:AXGN) investors are sitting on a loss of 76% if they invested five years ago (Simply Wall St.)
Feb-13-23 07:00AM	Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer (GlobeNewswire)
Jan-09-23 07:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022 (GlobeNewswire)
Jan-05-23 07:00AM	Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits (GlobeNewswire) +5.53%
Jan-04-23 07:00AM	Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference (GlobeNewswire)
Jan-01-23 08:52AM	AxoGen, Inc. (NASDAQ:AXGN) is favoured by institutional owners who hold 65% of the company (Simply Wall St.)
Dec-19-22 07:00AM	Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	SENIOR ADVISOR	Sep 05 '24	Proposed Sale	13.00	150,000	1,950,000		Sep 05 04:33 PM
JOHNSON JOHN	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	29,016	Sep 04 09:13 PM
NEELS GUIDO J	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	90,816	Sep 04 09:11 PM
Levine Alan M	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	40,816	Sep 04 08:58 PM
Burke William P. Mr.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	28,557	Sep 04 08:52 PM
THOMAS PAUL	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	32,052	Sep 04 08:33 PM
TYNDALL JOSEPH A.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	22,557	Sep 04 07:52 PM
Wendell Amy McBride	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	102,899	Sep 04 05:18 PM
Donovan Michael Patrick	Officer	Aug 21 '24	Proposed Sale	12.42	28,003	347,810		Aug 21 04:31 PM
GREG FREITAG	Director	Aug 13 '24	Proposed Sale	11.17	15,000	167,520		Aug 13 05:00 PM
Zaderej Karen L.	SENIOR ADVISOR	Aug 12 '24	Proposed Sale	10.00	200,000	2,000,000		Aug 12 10:59 AM
Freitag Gregory Gene	Director	Jun 04 '24	Option Exercise	0.00	11,904	0	283,498	Jun 06 04:49 PM
Zaderej Karen L.	CEO	Mar 16 '24	Option Exercise	0.00	110,322	0	1,157,593	Mar 25 09:43 PM
Zaderej Karen L.	CEO	Mar 21 '24	Sale	7.68	39,280	301,670	1,124,565	Mar 25 09:43 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '24	Option Exercise	0.00	18,675	0	180,615	Mar 25 09:40 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 21 '24	Sale	7.68	4,578	35,159	165,661	Mar 25 09:40 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Option Exercise	0.00	2,500	0	58,604	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 16 '24	Option Exercise	0.00	25,406	0	58,250	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Sale	7.68	6,881	52,846	52,999	Mar 25 09:37 PM
Donovan Michael Patrick	VP Operations	Mar 16 '24	Option Exercise	0.00	24,575	0	58,846	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 21 '24	Sale	7.68	6,033	46,333	37,992	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 07 '24	Sale	8.81	36,310	319,891	35,708	Mar 08 05:33 PM
Freitag Gregory Gene	Director	Mar 07 '24	Sale	9.00	25,000	225,000	271,594	Mar 08 05:31 PM
MARIANI PETER J	EVP & Chief Financial Officer	Dec 11 '23	Sale	7.50	12,500	93,809	63,603	Dec 13 04:07 PM

EYPT

EyePoint Pharmaceuticals Inc

AXGN

Axogen Inc.

Upgrade your FINVIZ experience